Ryan (for Mani Foroohar)'s questions to Mirum Pharmaceuticals Inc (MIRM) leadership • Q4 2024
Question
Ryan, on behalf of Mani Foroohar, asked about LIVMARLI's current market penetration in the Alagille syndrome population and the primary drivers for future U.S. growth.
Answer
CEO Chris Peetz stated that U.S. penetration is approximately 40% for the eligible Alagille syndrome population, leaving significant room for growth. He identified future growth drivers as a combination of further penetration into the prevalent population, new patient diagnoses, and dose increases from weight-based dosing.